Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Express Scripts
Dow
Baxter
Colorcon

Last Updated: August 19, 2022

SYMPAZAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Sympazan patents expire, and when can generic versions of Sympazan launch?

Sympazan is a drug marketed by Aquestive and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and sixty-two patent family members in nineteen countries.

The generic ingredient in SYMPAZAN is clobazam. There are ten drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the clobazam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Sympazan

A generic version of SYMPAZAN was approved as clobazam by AMNEAL on October 22nd, 2018.

  Try it Free

US Patents and Regulatory Information for SYMPAZAN

SYMPAZAN is protected by two US patents.

Patents protecting SYMPAZAN

Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aquestive SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SYMPAZAN

See the table below for patents covering SYMPAZAN around the world.

Country Patent Number Title Estimated Expiration
Japan 2006516634 See Plans and Pricing
Japan 2011050394 MULTI-LAYER FILM HAVING UNIFORM CONTENT See Plans and Pricing
World Intellectual Property Organization (WIPO) 2007030754 See Plans and Pricing
Mexico 2015013184 COMPOSICIONES DE PELICULAS SUBLINGUAL Y BUCAL. (SUBLINGUAL AND BUCCAL FILM COMPOSITIONS.) See Plans and Pricing
Japan 2005528328 See Plans and Pricing
Canada 2802671 COMPOSITIONS EN FILM POUR LA DISTRIBUTION D'AGENTS ACTIFS (FILM COMPOSITIONS FOR DELIVERY OF ACTIVES) See Plans and Pricing
Japan 2016513736 舌下及び頬用フィルム組成物 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
AstraZeneca
Moodys
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.